BioWorld Asia

May 5, 2010

Oxford Immunotec Raises $26M to Boost T-Cell Tests Worldwide

LONDON - Oxford Immunotec Ltd. raised $26 million in a fourth-round funding, which it said will enable it to increase sales of its T-cell diagnostic for tuberculosis and take the company through to profitability. (BioWorld International) Read More

Asian Pacific Biotechs Branch Out from Health to White Tech

Study Pinpoints Viral RNA Targets for Future Drugs

Huntington's Drug Snagged on Statistics; Another Trial Needed?

BIO in Chicago: BioWorld Waxes Nostalgic, Biotech Perseveres

Affimed Plans to Take Antibodies into Clinic with $26M Series C

Protox's $75M Kissei Deal May Set Stage for Larger Alliances

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...